Literature DB >> 23890973

Molecular snapshot of Mycobacterium tuberculosis population structure and drug-resistance in Kyrgyzstan.

Igor Mokrousov1, Jainagul Isakova, Violeta Valcheva, Almaz Aldashev, Nalin Rastogi.   

Abstract

Kyrgyzstan is a post-Soviet country in Central Asia marked with high incidence and mortality rates of tuberculosis (TB). The present study provided first assessment of Mycobacterium tuberculosis population structure and drug-resistance in civilian population here. The collection included 103 M. tuberculosis DNA samples subjected to the analysis of rifampin and isoniazid resistance mutations and spoligotyping. The major spoligotype-defined families were Beijing (n = 62), T (n = 14), LAM (n = 9), Ural-2 (n = 6) and Ural-1 (n = 3). Genotypically, 20 isolates were RIF-resistant, 28 were INH-resistant, 17 were multidrug-resistant. Drug resistant isolates were more prevalent among Beijing than non-Beijing groups (P = 0.03). The predominance of the mainly "Russian" spoligotypes among the non-Beijing strains (LAM-RUS and Ural-1) in this study along with previously demonstrated prevalence of the Russia-specific subtype of the Beijing family in Kyrgyz prison (Mokrousov et al., 2009) suggest that the current population structure of M. tuberculosis in Kyrgyzstan has been mainly formed within the course of the 20th century when the country was a part of the Russian Empire and Soviet Union. On the other hand, a prevalence of the Asia-specific Ural-2 type in the oldest age group (68-85 years old; P < 0.0001) may present a heritage of the more distant historical events. In summary, we suggest: (i) a clear shift of the local M. tuberculosis population structure during the last 100 years and (ii) a critical impact of the Beijing genotype on the current situation with drug resistant TB in Kyrgyzstan.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; Kyrgyzstan; Molecular epidemiology; Tuberculosis

Mesh:

Year:  2013        PMID: 23890973     DOI: 10.1016/j.tube.2013.05.008

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Spoligotype and Drug Susceptibility Profiles of Mycobacterium tuberculosis Complex Isolates in Golestan Province, North Iran.

Authors:  Noormohamad Mansoori; Farzam Vaziri; Sirus Amini; Sharareh Khanipour; Shahin Pourazar Dizaji; Masoumeh Douraghi
Journal:  Infect Drug Resist       Date:  2020-07-01       Impact factor: 4.003

2.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

3.  Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.

Authors:  Jainagul Isakova; Nurmira Sovkhozova; Denis Vinnikov; Zoy Goncharova; Elnura Talaibekova; Nazira Aldasheva; Almaz Aldashev
Journal:  BMC Microbiol       Date:  2018-03-22       Impact factor: 3.605

4.  Resistance of Mycobacterium tuberculosis strains to Rifampicin: A systematic review and meta-analysis.

Authors:  Seifu Gizaw Feyisa; Ahmed Abdulahi Abdurahman; Worku Jimma; Eshetu Ejeta Chaka; Jalil Kardan-Yamchi; Hossein Kazemian
Journal:  Heliyon       Date:  2019-01-01

5.  Mycobacterium tuberculosis RD-Rio Strain in Kazakhstan.

Authors:  Yuriy Skiba; Igor Mokrousov; Dilyara Nabirova; Anna Vyazovaya; Elina Maltseva; Natalya Malakhova; Gulnara Ismagulova; Ilva Pole; Renate Ranka; Zhanar Sapiyeva; Shakhimurat Ismailov; Daphne Moffett
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

6.  Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.

Authors:  Anna Engström; Uladzimir Antonenka; Abdylat Kadyrov; Gulmira Kalmambetova; Katharina Kranzer; Matthias Merker; Olim Kabirov; Nargiza Parpieva; Asliddin Rajabov; Evgeni Sahalchyk; Zayniddin Sayfudtinov; Stefan Niemann; Harald Hoffmann
Journal:  BMC Infect Dis       Date:  2019-10-29       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.